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INTRODUCTION  
 
                     In India, COPD is the second most common lung disorder after 
pulmonary tuberculosis. The disease frequently encountered in middle aged 
patients and also COPD increasing public importance around the world. 
Estimates suggest that COPD will rise from the 6th to the 3rd most common 
cause of death worldwide by 2020. 
AIMS AND OBJECTIVES  
To estimate P wave vertical axis and FEV1 in patients with features of COPD. 
To study P wave vertical axis inversely correlating with FEV1. 
TO analyse whether P wave vertical axis can be substitute for FEV1 in 
assessing the severity of COPD. 
METHODS AND MATERIALS 
 The study is to be conducted on 100 patients of Government Rajaji 
Hospital, who are all attending internal medicine and thoracic medicine op with 
clinical features and ECG changes of COPD .inclusion criteria: Age >45 year, 
Normal sinus rhythm with ECG change , past medical history of 
COPD,Imaging studies with COPD changes, Pulmonary function tests with 
COPD changes. Exclusion criteria: Congenital heart disease ,valvular heart 
disease, Cardiomyopathy.  
STUDY PROTOCOL  
                      The design for study is Observational study done in  the  
period of  July 2014 to September  2014 with simple Statistical analysis 
and participants are Patients attending in medicine and thoracic medicine 
op with clinical features and ECG changes of COPD 
RESULTS 
                         Among 100 patients, 17 patients had P wave vertical axis of 65-
75 degree,19 patients had p wave vertical axis of 71-75 degree,20 patients had P 
wave vertical axis 76-80 degree,44 had P wave vertical axis of >80 degree. P 
wave vertical axis>80 degree is superior to P wave vertical axis 75 -80 degree is 
correlating with COPD severity and statically significant as p value is < 0.005. 
CONCLUSION 
                    From our study we concluded that , increasing age is 
associated with severity of the disease .Males are more commonly 
affected then females because of smoking.occupational exposure to risk 
factors confounding  the risk of developing the disease when associated 
with smoking. Incidence of pulmonary hypertension and right ventricular 
dilatation increase with increase  in severity of the diseases. p wave 
vertical axis is directly proportional  to severity of COPD and inversely 
correlating with the FEV1 of predicted . 
KEY WORDS    
Vertical P-wave axis, the electrocardiographic synonym for pulmonary 
emphysema, The electrocardiogram in pulmonar emphysema,electrocardiogram 
in chronic cor pulmonale,Pulmonary emphysema: classical, quasi-diagnostic 
ECG 
  
HISTORICAL PERSPECTIVE 
         The beginning of modern chest medicine can be traced to the classic 
volume by Laennec, “A treatise on diseases of the chest” which appeared in 
1821 laid the corner stone of modern chest medicine. 
          In his treatise, Laennec, devoted one chapter to “Pulmonary Catarrh or 
Bronchitis” and emphysema. The chapter on bronchitis distinguishes between 
acute and chronic form and sub divides chronic bronchitis into two types – the 
humid (Copious Expectoration) and dries (Scarcely any Expectoration). He 
identified “Dilatation of air cells” as the essential feature of emphysema. 
       Recognition of chronic bronchitis as a potentially grave illness rather than 
as a trivial but not disabling disease had to wait the “London Fog” of 1953, 
which was brought about by bad weather and air pollutants, carried with it a 
surge in morbidity and mortality due to chronic lung disease . 
After World War II, clinical investigations of pulmonary disease were provided 
with a new diagnostic armamentarium; Pulmonary Function tests were extended 
beyond simple spirometry and innovative techniques were developed for 
assessing the distribution of gases within the lungs which greatly improved our 
understanding of COPD. 
 
 
  
INTRODUCTION 
                     In India, COPD is the second most common lung disorder after 
pulmonary tuberculosis. The disease frequently encountered in middle aged 
patients and also COPD increasing public importance around the world. 
Estimates suggest that COPD will rise from the 6th to the 3rd most common 
cause of death worldwide by 2020.  
    Emphysema of any pathogenesis nearly always  due to chronic obstructive 
pulmonary disease and rarely due  to alpha 1 antitrypsin deficiency produce a 
state of abnormal  lung hyperinflation and has been shown to carry on 
association with a vertical frontal p wave axis.  
    Patients with COPD show that vertical p wave  axis in ECG and forced 
expiratory volume in pulmonary  function test were inversely correlating, so 
ECG can be used  to assess the severity of COPD  in place of pulmonary 
function test and also vertical P wave axis (>60) during a  sinus rhythm can be 
easily detected by a simple glance at the electrocardiogram. 
The present study is to compares the P wave vertical axis, which is    
reproducible, patient friendly, less procedure related complication, minimal 
time consuming against the more cumbersome method of FEV1 measurement in 
assessing the severity  of COPD. 
 
  
AIMS AND OBJECTIVES  
 
 
 
1. To estimate P wave vertical axis and FEV1 in patients with features of 
COPD. 
 
2. To study P wave vertical axis inversely correlating with FEV1. 
 
3. TO analyse whether P wave vertical axis can be substitute  for FEV1 in 
assessing the severity of COPD  
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
DEFINITION 
                         Chronic obstructive pulmonary disease is Characterised by 
persistent airflow limitation that is not fully Reversible, usually progressive and 
associated with a chronic Inflammatory response in the airway and the lung to 
noxious . 
Particles or gases. 
1. EMPHYSEMA  
Emphysema is defined as destruction and enlargement in  The lung 
alveoli. 
2. CHRONIC BRONCHITIS 
This condition associated with excessive mucous Production sufficient to 
cause cough with expectoration At least 3 months a year for more than 3 
consecutive years 
3. SMALL AIRWAY DISEASE 
 
 
 
 
  
 
EMPHYSEMA 
Types of emphysema 
 
  
Centriacinar emphysema: proximal portion of respiratory unit and central part 
are destructed and enlarged. Apices and upper lobes are predominantly 
involved. This predominantly seen in male patients with chronic bronchitis  
Panacinar emphysema: these type of emphysema seen in alpha 1 antitrypsin 
deficiency individual.it is particularly involve lower lobes because lower lobes 
are rich in blood supply .protease rich enzymes are present in neutrophils that 
destruct the alveoli which is not able to inhibit by anti-protease enzymes in this 
individuals due to deficiency. 
Paraseptal emphysema: this type of emphysema can lead to pneumothorax 
because its mainly found near to pleura. Distal acinus is predominantly 
involved. 
Irregular emphysema: this could be seen in any type of emphysema. 
SPECIAL VARITIES OF EMPHYSEMA 
Compensatory emphysema: in response to pathology to same lung or opposite 
lung, normal lung become hyper inflate as a compensatory mechanism. Here the 
alveoli septea are not destroyed .clinically there is no signs of emphysema. 
Mediastinal emphysema: this type of emphysema occurs due to rupture of over 
distended alveoli .this may occur in following condition 
a.severe bronchial asthma 
  
Rupture of emphysematous bulle 
Rupture of oesophagus 
Subcutaneous emphysema: this type of emphysema occur due to escaped air 
tracks up into the subcutaneous tissues of neck. If the COPD patient present 
with neck swelling, we have to think in terms of subcutaneous emphysema 
possibility. 
CHRONIC BRONCHITIS  
It is subdivided into  
a.simple chronic bronchitis 
b.chronic mucopurulent bronchitis 
c.chronic bronchitis with obstruction  
REID INDEX 
Reid index is expressed as ratio of sub mucosal glands to that of bronchial wall. 
In normal individuals, its 0.44±0.09 
In chronic bronchitis, its 0.52±0.08 
When the sub mucosal layer thickness >50% of bronchial wall thickness it is 
highly suggestive of chronic bronchitis . 
 
  
DIFFERENTIATING FEATURE BETWEEN EMPHYSEMA AND 
CHRONIC BRONCHITIS  
FEATURES PREDOMINANT 
EMPHYSEMA 
(PINK PUFFER) 
PREDOMINANT 
BRONCHITIS 
(BLUE 
BLOATER) 
Age of onset 6th decade 5th decade 
Cough After dyspnoea Before dyspnoea 
Dyspnoea Severe Mild 
Sputum Scanty,mucoid Copious, purulent 
Infections Less common Common 
Respiratory 
insufficiency 
Often terminal Repeated attacks 
Chest x ray  Hyperinflation ± 
bullous changes; 
small heart 
Increased 
bronchovascular 
markings; large 
heart 
Paco2 (mm Hg) 35 – 40 50 – 60 
Pao2 (mm Hg)  65 -70  45-60 
Pulmonary 
hypertension 
Mild Moderate to severe 
  
Cor pulmonale Preterminal stage Common 
Diffusing capacity Decreased Normal to slight 
reduction 
Lung compliance Increased  Normal 
GOLD CRITERIA FOR COPD SEVERITY 
GOLD stage Severity Spirometry 
I Mild FEV1/FVC < 0.70 
    FEV1≥80% predicted 
II Moderate FEV1/FVC < 0.70 
    50% ≤ FEV1 < 80% 
predicted 
III Severe FEV1/FVC < 0.70 
    30% ≤ FEV1 < 50% 
predicted 
IV Very severe FEV1/FVC < 0.70 
    FEV1 < 30% predicted 
or FEV1 < 50% 
predicted plus chronic 
respiratory failure 
 
 
  
 
 
EPIDEMIOLOGY 
                COPD is expected to be the third most common cause of  mortality 
and the fifth for loss of  DALY worldwide according to Global Burden of 
disease study. 
 PREVALENCE IN INDIA 
          The exact prevalence in our country could not be  
ascertained because of misdiagnosis, underassessment, lag of extensive 
studies, poor statistical information. The prevalence rate varies from 2 to 22 
per cent in males and 1.2 to 20 percentage in females. Recently ICMR has 
done the INSEARCH study in four cities and reported prevalence of 5% in 
males and 3.2% in females more than 35 years of age. The total population 
affected by the disease has increased to 14.84 million in 2011 from 6.45 
million in 1971. In India the sex ratio and the smoker to non smoker ratio are 
not as high when compared to western statistics. The reason for disparity is 
biomas fuel combustion which is important risk factor in women more so in 
villages. Data on mortality statistics are limited; 7% mortality has been 
attributed to chronic respiratory illness. 
 
  
 
RISK FACTORS INFLUENCING ONSET AND 
PROGRESSION 
SMOKING  
      Tobacco smoking is the most important and the well-studied risk factor. 
About 85% of COPD is related to smoking. The remaining 15% is attributed 
to smoke from burning biomass fuels like woods, from occupational exposure 
to dust and smoke and cow dung for cooking.  
The effect of smoking on decline lung function has been proved in many 
studies. cigarette smokers show high annual rate of decline in FEV1 of about 
50 ml, this is nearly double the average value of 30 ml annually present in 
non-smokers .even though ,there is considerable variation in FEV1,with some 
smokers showing very rapid rate of decline. The decline in FEV1 might be 
faster in natural history of disease before COPD is established.  
 But still not all smoker developed the disease and even among those who 
smoke there are variations in response to the duration of smoking which 
suggest  that other factors particularly environment modulate, the effect of 
smoking, content of smoke such as tar, nicotine ,other constituents and genetic 
in these patients. 
Mortality due to COPD is twofold higher in  smokers who smoke ≥ 
25cigrattes per day then those with smoking fewer than 15 cigarettes per day  
  
 
         
 
  PASSIVE SMOKING 
There is statistically significant correlation showed in relation with lung 
cancer in passive smokers .these is shown mainly in patients who are 
chronically exposed since childhood with significant lower of FEV1 in 
adulthood.  
AIRWAY RESPONSIVENESS 
Though the concept of airway hyper responsiveness is proved beyond doubt in 
bronchial asthma, in COPD there are conflicting reports even though there are 
recent studies supporting the airway hyper responsiveness in COPD patients. 
RESPIRATORY INFECTIONS 
Infections associated with risk 
1. Childhood respiratory infections 
2. Previous history of tuberculosis even when adequately treated with ATT. 
3. Inadequately treated bronchial asthma 
INDOOR AIR POLLUTIONS 
Though in developed countries, smoking is the major risk factor, in 
developing countries like ours causes other than smoking contribute one third 
  
to half of all cases. Among them chronic exposure to carbon monoxide, 
HCHO and nitric oxide and sulphur dioxide and others released from biomass 
fuel combustion is the important risk factor particularly in female patients. 
WHO identified that, if the sulphur dioxide level ≥150 microgram /m3 shows 
increased morbidity in terms of symptoms and hospital admissions in adult 
COPD.  
Those who have poor cardiopulmonary reserve and  elderly people show 
increased mortality if the sulphur dioxide level or black smoke 
≥500microgram/m3  
 
       GENES  
The difference in expression of disease among smokers could possibly be 
explained by the genetic factors. Alpha 1 antitrypsin deficiency due to alteration 
in SERPINA 1 locus encoding the enzyme is the only proven genetic factor 
related to the COPD. 
Allele 
 
Alpha 1 Anti trypsin 
M Normal 
 
S Slightly reduced 
 
Z Markedly reduced  
 
Null  Absent 
  
 
 
 
 The above picture shows that pattern of PiM,PiZ and Pimz alpha 1 AT on 
isoelectric focus. Because of its multiheterogenisity ,it appear as multiple 
bands.PiM and PiZ shows different band patterns, while PiMZ shows 
combination of both PiM and PiZ. 
  
 
 
One has to suspect alpha 1 antitrypsin deficiency as the cause in patients with  
1. Age of onset <40 years of age 
2. Insignificant history of smoking 
3. Predominant lower lobe involvement. 
4. Necrotizing panniculitis(weber Christian disesase) 
5. C ANCA positive vasculitis (wegeners granulomatosis) 
6. Early onset of emphysema in family members or non-smoking related 
emphysema. 
7. Bronchiectasis without other aetiology 
 
PiZZ is the most common form of severe alpha 1 antitrypsin deficiency 
showing greatly accelerated decline in FEV1 . 
PiM is the commonest allele in all population and the most common 
genotype is PiMM. 
Treatment for this subset of individuals is weekly intravenous administration 
of alpha 1 antitrypsin. 
AGE 
  
Increasing age  physiologically decreases the function of lung which may 
also contribute. 
 
In vertical axis FEV1 plotted and horizontal axis age of the person is plotted. 
This shows that ,in non-smoker or not susceptible to smoking will lose 25% of 
his /her lung function throughout his life. Those who  smoke or are  susceptible 
to smoking will have decline in lung function rapidly as shown in this picture. 
Even though abnormal lung function is detected in these patients ,symptoms 
develop only when the lung function reduce to less than 50% 
  
 
 
The above picture represents natural history of COPD with hypothetical case 
scenario who continues smoking upto the age of 45 years then he discontinues 
the smoking.here once the patient stops smoking before development of 
symptoms the lung fuction goes to normal range. Once the patient who is 
detected to have abnormal lung function before the development of symptoms 
cessation of smoking can revert  the  lung function to normal .  
 
  
OCCUPATION  
There is causal correlation between occupational dust exposure and 
development of mucus hyper secretion. Coal miner’s shows development of 
small excess decline in FEV1 and increased mortality. 
Those who are exposed to welding fumes are also showing development of 
COPD and workers who are exposed to cadmium also develop COPD in 
later days. 
   GENDER 
In the past , the prevalence and mortality were more among men. As on date 
it is almost equal among men and women. When compared to men, women’s 
susceptibility to the ill effects of tobacco smoking is significantly higher. 
    LUNG GROWTH AND DEVELOPMENT 
The factors that affect the lung growth and development During the 
intrauterine life, and childhood increases an individual’s susceptibility to 
develop COPD in the later years of life. 
LOW SOCIOECONOMIC STATUS 
The risk of developing COPD is inversely proportional to socioeconomic 
status 
 
  
PATHOPHYSIOLOGY 
Pathological changes in the lungs lead to corresponding physiological 
changes characteristic of the disease which occur in the following order: 
Mucus hyper secretion 
 
Ciliary dysfunction 
 
Airflow limitation 
 
Pulmonary hyperinflation 
 
Gas exchange abnormalities 
 
Pulmonary hypertension 
 
  
Cor pulmonale 
   AIRFLOW LIMITATION 
Airflow limitation due to decreased airway calibre and increased airway 
resistance, impaired elastic lung recoil during expiration manifest in 
spirometry as a reduction in the ratio of FEV1/FVC < 0.7 (FEV1- forced 
expiratory volume in 1 second, FVC- forced vital capacity) and reduced 
forced bronchodilator FEV1 predicted value is a cardinal feature for the 
disease diagnosis and dividing into stages. 
FVC at 6 seconds (FEV6) in patient with COPD is adequate and equivalent  
to FVC in individuals with severe obstruction. 
During forced expiration there is airway instability and narrowing ,this the 
cause for discrepancies between inspiratory and expiratory flow. 
From the flow pressure curve we can quantify the diminished elastic recoil 
and increased airway resistense by reduced maximal expiratory air flow. 
Decreased elastic recoil  shows –normal slope with premature termination. 
Increased airway resistence shows –less steep slope  
  
 
MEFV –maximum expiratory flow volume 
MIFV-maximum inspiratory flow volume 
LEFT-shows normal subject 
MIDDLE-mild airway obstruction due to COPD 
RIGHT-shows severe obstruction due to COPD 
HYPERINFLATION 
In COPD patients there is hyperinflation as shown by increased RV and 
increased ratio of RV/TLC and later increase in TLC. ( RV- residual volume, 
TLC – total lung capacity) 
  
Mechanism 
The primary mechanism during expiration from small airways and alveoli is 
driven from the inward elastic recoil pressure of the lung which is also 
contributed by the counteracting thoracic wall outward pressure. At the end 
of tidal expiration both these balance each other resulting in particular 
amount of air remaining in the lungs named as FRC(Functional residual 
capacity). In COPD patients, due to destruction of lung parenchyma the 
inward pressures are low and it comes into equilibrium with the outward 
pressure at increased volumes of FRC resulting in hyperinflation 
. 
  
 Hyperinflation may be an advantage as it favours  conservation of 
maximum expiratory airflow by the following ways 
1. Increase lung volume  
     2.  Increase elastic recoil pressure 
    3. Enlarge airway lumen 
    4. Decrease airway resistance 
However hyperinflation has untoward effects on mechanics of the thorax. 
1. increase work of breathing 
2. induce dyspnea 
But hyperinflation of the lung keeps the diaphragm at a mechanical 
disadvantage i.e flattening of diaphragm resulting in functional diaphragmatic 
paralysis.this flatting of diaphragm leads to number of ill effects.those are 
              1. Because of loss of apposition zone between diaphragm and 
abdominal wall, during inspiration positive abdominal pressure not transmitted 
as virtually to chest. This leads to hampering rib cage movement and impairing 
inspiration. 
  
           2. Because of flatting of diaphragm muscle fibres are shorter than those 
of more normally curved diaphragm, this ultimately lead to less effective 
generation of inspiratory pressure. 
Concurrent with hyperinflation, in patient with COPD inspiratory capacity also 
commonly reduced. This finding has prognostic significance that is independent 
of FEV1.   
   
   GAS EXCHANGE 
               The partial pressure of oxygen will be maintained until FEV1 s less 
than 50% of the predicted value and co2 retention will be observed only when 
the FEV1 is less than 25% of the predicted value. Gas exchange impairment in 
COPD is mainly due to the mismatch between the ventilation and perfusion. 
Large bullae will  complicate this issue further because they are non-functioning 
airspaces with both poor perfusion and ventilation and moreover they occupy a 
significant volume of lung and hence compress and compromise the adjacent 
functional parenchyma. 
V/Q MISMATCH 
The characteristic feature of COPD is ventilation perfusion mismatch, this 
heterogeneous process affect not only the lung parenchyma but also affect the 
airways. 
  
Ventilation – perfusion mismatching is the primary cause for the reduced Po2 
that occur in COPD.From this view, modest increase in inhaled oxygen are 
effective in treatment of COPD. 
 
 
 
DYSPNEA 
Most of the COPD patient seek medical care only when they develop 
dyspnea.dyspnea impairs their day to day activites and affect  the qualities of 
life.patient present with complaints of dypnea only when the FEV1 fall to 
<60% of expected. 
  
The mechanism for breathlessness in COPD is +currently not well known. 
Neural signals pertaining to abnormalities of chest wall and airway mechanics 
seems to be important. 
1.An increased feeling of expenditure relating to the pressure required from 
respiratory muscles relating to their maximum pressure generating capacity.  
2.Impuse of “length-tension inappropriateness “from the respiratory muscles 
because of hyperinflation 
3.Also,signals from airways  leading abnormal dynamic compression 
during exhalation have been described. 
4.except in acute scenario hypercarbia and hypoxia play  little role in 
dyspnoea. 
   
  
         PATHOGENESIS 
ACTIVATION OF MACROPHAGES 
Macrophages are the cells found in the normal lower airways. Cigarette 
smoke contains oxidants which inactivates the histone deacetylase II with 
a resulting increase in acetylated chromatin thereby promoting increased 
transcription of pro inflammatory cytokines and matrix metalloproteinase. 
This pro inflammatory cytokines recruits neutrophils and stimulates 
neutrophil elastase. Macrophage secreted matrix metalloproteinase and 
neutrophil secreted elastase acts together and causes lung damage. 
  
LOSS OF CILIA 
Cigarette smoke causes loss of cilia in the airways and predispose to 
bacterial infection with neutrophilia. 
 
 
 
ANTIELASTASE HYPOTHESIS 
Alpha 1 anti trypsin deficiency 
   Neutrophils in the alveoli are stimulated by variable triggers which get 
activated and recruited and they release the granules such as proteinases, 
catapsins, elastase and matrix metalloproteinase and also reactive oxygen 
species which inhibit alpha 1 anti trypsin. Because of deficiency of alpha 
1 anti trypsin , counteraction with granules released by neutrophis is 
decreased and this results in destruction of air spaces 
SMOKING 
In smokers both neutrophils and macrophages are increased in alveoli. 
Neutrophils upon activation release the above said proteases and activate  
macrophages release a variety of cytokines, ROS, chemokines and a 
variety of matrix mataloproteinases which are not inhibited by alpha 1 
antitrypsin rather these enzymatically degrade alpha 1 antitrypsin and 
thus enhancing pulmonary destruction several fold. CD8 lymphocytes 
  
increase apoptosis of alveoli and CD4 cells triggers autoimmunity against 
native lung tissue. 
 
 
 
 
 
 
OXIDANT STRESS 
The normal lung contains high amount of anti oxidants such as 
glutathione to handle the oxidant stress. Smoking activates inflammatory 
cells by the above said mechanism and releases free radicals which shift 
the balance towards oxidant stress which inactivates anti proteases 
  
causing lung destruction in patients even with normal alpha 1 AT. 
Oxidant stress also result in loss of surfactant, reduction in elastin 
synthesis, Extra cellular matrix apoptosis. 
 
 
         
 CLINICAL PRESENTATION 
HISTORY 
SYMPTOMS 
1. Chronic cough 
2. Expectoration 
3. Dyspnea on exertion, insidious in onset and gradually progressive 
over time. Sudden worsening of dyspnea could be either on due to 
exacerbation or pneumothorax or other complications. 
4. Wheeze 
5. Loss of weight – in severe disease ( other causes should be ruled out 
before attributing it to the disease per se i.e. bronchogenic carcinoma) 
     
  
 
       SIGNS: 
The physical examination might be completely normal in patients in the 
beginning stages till there is significant deterioration in pulmonary 
function. 
GENERAL EXAMINATION 
1. Stigmata of smoking – nicotine stains, etc. 
2. Cyanosis may be present. 
3. Clubbing is not a sign of disease per se and if clubbing is present one 
should search for carcinoma of lung. 
  
4. Pedal edema, ascites, elevated JVP  due to pulmonary hypertension 
and cor pulmonale. 
5. Patient may have hypoxemia. 
RESPIRATORY SYSTEM EXAMINATION 
a. Patient with severe disease may have acting accessory muscles of 
respiration with the patient assuming “tripod” position to enhance the 
synergistic action of these muscles. 
b. Hoover’s sign – the movement of costal margins towards the midline 
during inspiration. 
c. Signs of hyperinflation – barrel shaped chest, hyper resonance on 
percussion 
d. On auscultation patient may have prolonged expiratory phase, 
diminished intensity of breath sounds, expiratory wheeze. 
e. Signs of pulmonary hypertension and cor pulmonale – loud P2 may 
not be present due to hyperinflation, tricuspid regurgitation murmur 
can be heard. 
 
 
 
 
 
  
DIFFERENTIAL DIAGNOSIS 
1. Bronchial asthma – distinguished by near total post bronchodilator 
FEV1 reversibility. 
2. Bronchiectasis – differentiated by symptoms like hemoptysis, 
presence of clubbing and radiography. 
3. Cystic fibrosis – history since childhood, recurrent infections, 
presence of other features such as cirrhosis. 
4. Broncho pulmonary mycosis 
5. Central airway obstruction such as developmental anomalies, 
tumours, stenosis  - differentiated by history and PFT using flow-
volume loops. 
COMPLICATIONS 
1. Recurrent lung/airway infection 
2. Bronchogenic carcinoma 
3. Cor pulmonale and pulmonary hypertension 
4. PTE 
5. Pneumothorax especially in those with emphysema 
6. Cardiovascular effects – CAD, arrhythmias. 
             RADIOGRAPHY 
            XRAY CHEST 
  
1. CHRONIC BRONCHITIS – increased bronchovascular 
markings  
 
2. EMPHYSEMA – hyper inflated lung fields 
                             Diaphragm flattening 
                             Decreased peripheral vascular markings  
                                            Bulla 
 
 
 
  
3. Pulmonary hypertension – enlarged main and right descending 
pulmonary artery. 
4. To look for co morbidities and complications like malignancy, 
pneumothorax etc. 
 
COMPUTED TOMOGRAPHY 
1. Not routinely done for diagnostic purposes 
2. To assess patients fitness for surgical management. 
LABORATORY TESTS 
PULMONARY FUNCTION TEST: 
1. FEV1/FVC < 0.70 
2. TLC, FRC, RV may increase often more than normal with disease progression. 
 Apart from diagnostic utility, FEV1 is also used to monitor treatment response 
and worsening FEV1  is a poor prognostic factor. 
ABG : 
1. Normal in early stages. 
2. To determine the degree of hypoxemia and the acid base status and to 
differentiate between acute exacerbations and chronic respiratory failure. 
3. Yearly assessment is recommended. 
  
TREATMENT 
STABLE PATIENTS 
Survival improving strategies 
1. Smoking cessation 
2. Oxygen 
3. Lung volume reduction surgery 
Other management strategies are to the relief of symptoms, improving the 
quality of life and to reduce exacerbations. 
DRUGS 
BRONCHODILATORS 
These drugs are the mainstay of management in that they provide symptom 
relief and enhance the well-being of patient but do not prevent the decline in 
FEV1. 
INHALED BETA2 AGONISTS : 
1. Short acting beta 2 agonist : used in all stages of the disease ‘on demand’ basis 
to provide immediate relief from dyspnoea and not to be used on a routine basis. 
Drugs used are salbutamol and levo salbutamol. 
2. Long acting : used on a scheduled basis as maintenance therapy to provide 
sustained relief. 
Drugs commonly used are formoterol, salmeterol. 
  
                         Side effects; tachycardia, tremor, decrease in serum     
potassium. 
                    INHALED ANTI-CHOLINERGICS: 
1. Short acting : for symptom relief similar to short acting beta 2 agonists but are  
devoid of their sympathetic side effects and also has prolonged action compared 
to them. 
Drug used is ipratropium. 
2. Long acting : for maintenance therapy 
Side effects : dryness of mouth, primary angle closure glaucoma is an absolute 
contra indication, symptoms of BPH may aggravate. 
             COMBINATION THERAPY 
               As the disease worsens, combination therapy with long acting 
sympathetic and anticholinergic provides maximum symptom benefit by 
synergistic mechanisms rather than single drug alone.  
CORTICOSTEROIDS 
INHALED : 
ICS are not to be used as a single agent in management of these patients but 
used in combination with other inhaled bronchodilators. 
Indication : 
  
1. Stage 3 disease 
2. ≥2 exacerbations / year 
Side effects : 
1. Oral candidiasis – prevented by mouth gargling after each use or by 
spacer. 
2. Hoarseness of voice. 
 
SYSTEMIC STEROIDS 
Oral steroids are not indicated in the regular treatment of stable patients because 
the adverse effects overweigh the benefits but they are important part of acute 
exacerbation treatment. 
METHYLXANTHINES 
Sustained release theophylline is commonly used in patients who do not have 
adequate symptom relief with inhalational therapy because of its effects on 
diaphragm function, reducing airway resistance and anti inflammatory action. 
Side effects: 
These drugs have a narrow therapeutic window and hence supervision is 
essential. 
CVS: increase heart rate, arrhythmia. 
  
CNS: tremor, decreases seizure threshold, insomnia. 
GIT: gastritis, nausea. 
ANTIBIOTICS – no role in stable patients. 
NON PHARMACOLOGICAL MEASURES 
OXYGEN 
Oxygen therapy improves the morbidity of the patient and reduces the mortality. 
Indications  
1. Arterial partial pressure of oxygen≤ 55 mm of hg or oxygen saturation by pulse 
oximetry≤ 88 % 
2. Arterial partial pressure of oxygen < 60 mm hg and oxygen saturation < 90% in 
the presence of pulmonary hypertension, Hct > 55% or cor pulmonale. 
VACCINATIONS 
For all stages of the disease yearly influenza vaccine and pneumococcal vaccine 
(zero dose and a booster after 5 years) 
 PULMONARY REHABILITATION 
      It is a multi system modality including respiratory exercises, psychological 
support, adequate nutrition that improves exercise tolerance, improves 
  
breathlessness and quality of life. Indicated in patients failing optimal medical 
therapy and also for severe disease.  
SURGICAL MANAGEMENT 
1. LUNG TRANSPLANTATION 
A.  Done either as one lung or sequential double lung transplant. 
B. Requirements include severe disease inspite of optimal medical management, 
poor quality of life, absence of other organ system dysfunction. 
C.  PHT and the region of lung involved are not contraindications. 
2. LUNG VOLUME REDUCTION SURGERY 
3. Patients with upper lobe emphysema and severely compromised exercise 
tolerance are model candidates. Presence of PHT/ cor pulmonale are contra 
indications. 
  
 
This picture shows that selection of patient for lung volume reduction 
surgery 
4. BULLECTOMY 
 
 
 
 
 
  
 
 
This above points suggest stages wise approach to patient with COPD. 
 
 
 
 
 
  
EXACERBATION OF COPD 
PRECIPITATIING CAUSES 
Infections 
1. Bacterial infections 
a. Pneumococcus 
b. Haemophilus influenza 
c. Moraxella catarrhalis 
d. Pseudomonas in special risk groups. 
2. Viral infections 
Environmental 
1. Pollution 
2. Exposure to toxic gases 
3. Climate changes 
SYMPTOMS 
1. Increase in cough 
2. Worsening dyspnoea 
3. Increased sputum with purulence 
4. Worsening general condition 
  
To assess the severity of exacerbation complete physical examination is 
mandatory. 
Investigations include  
1. X ray chest – to detect pneumothorax, consolidation 
2. ECG – to detect rhythm disturbance, most common being MAT 
3. ABG – to detect respiratory failure. 
Based on the severity patient general status, supportive care, presence of 
other co morbidities like CAD, diabetes, ABG measurement and the need for 
assist ventilation, the decision is taken whether the patient has to be treated 
at home or hospital or ICU. 
Detecting the COPD mortality in exacerbation of COPD, BODE index is 
very useful. 
 
 
 
 
 
 
  
BODE INDEX 
 
DRUGS 
BRONCHODILATORS 
Short acting beta agonists are used in primary treatment  for exacerbation of 
COPD, either alone or in addition with an anticholinergic delivered through 
nebulisation or inhalation if patient can perform. Those patients who are already 
on methyl xanthine, it should not be stopped as it causes deterioration but 
monitoring of drug level is mandatory. During an exacerbation theophylline 
should not be prescribed. 
CORTICOSTEROIDS 
For short course systemic corticosteroids either oral or parenteral is a important 
cornerstone in management of acute exacerbation because the decrease hospital 
Variable 0 1 2 3 
FEV1 (% of predicted) ≥65 50-64 36-49 ≤35 
Distance walked in 6 min (meters) ≥350 250-349 150-249 ≤149 
MMRC dyspnea scale 0-1 2 3 4 
Body mass index >21 ≤21   
  
stay improves lung function decreases the subsequent hospital admissions due 
to exacerbation. 
ORAL CORTICOSTEROIDS 
Prednisolone at a dose of 30 to 40 mg or its equivalent has to be given for 10 to 
14 days. 
 The proven advantages are early recovery, lung function improvement, 
improvement in arterial hypoxemia, decrease in length of hospital stay.  
INHALED CORTICOSTEROIDS 
Nebulised budesonide can be used as an alternative for oral corticosteroids. 
ANTIBIOTICS 
Pro calcitonin III – specific for bacterial infection could be used to guide 
antibiotic therapy. 
INDICATIONS FOR ANTIBIOTICS IN ACUTE EXACERBATION 
1. Increase in dyspnea 
2. Increase in sputum volume 
3. Purulent sputum 
4. Patient requiring mechanical ventilation. 
Duration 5 to 10 days. 
 
  
OXYGEN THERAPY 
Spo2 should be maintained ≥ 90%. Oxygen must be given and should not 
be with held for fear of respiratory depression due to removal of 
hypercarbic stimulus because it is very important to prevent tissue 
hypoxemia but care should be exercised in monitoring the patient. 
After 6 minutes of oxygen therapy ABG should be performed to ensure 
adequate oxygenation without acidosis. 
 Ventury masks are preferred because of it’s controlled delivery and its 
accuracy. 
NON INVASIVE POSITIVE PRESSURE VENTILATION 
Currently it is preferred for patients with COPD requiring mechanical 
ventilator support for reason like  
1. Discomfort to the patient is very less. 
2. Less risk of infections. 
3. It counter balances the disadvantage of  PSV and  CPAP when used 
alone. 
INDICATIONS FOR NIPPV INCLUDES 
1. Severe dyspnoea with respiratory muscle fatigue 
2. Respiratory acidosis 
To consider a patient for NIPPV any one of the above is essential. 
  
INDICATION FOR INVASIVE MECHANICAL VENTILATION 
1. Nov-invasive positive pressure ventilation failure 
2. Severe bradycardia 
3. Cardiac and or respiratory arrest 
4. Severe tachypnea 
5. Uncontrolled respiratory secretions 
6. Hemodynamic instability 
7. Aspiration 
8. Altered consciousness 
SYSTEMIC MANIFESTATION OF COPD 
It has been identified from the experiences in the past decades that 
inflammation is no longer confined to lungs in COPD and that GOLD 
definition of the disease at present includes ‘some significant extra 
pulmonary effects that may contribute to the severity in individual 
patients’.  Therefore the disease could be renamed as chronic systemic 
inflammatory syndrome. 
MARKERS OF SYSTEMIC INFLAMMATION IN COPD 
1. white blood cell count 
2. ferritin 
3. fibrinogen 
  
4. hsCRP 
5. TNF alpha receptor polymorphism 
6. TGF beta 1 
7. Interleukins 
8. ROS 
These markers are present in mild markers of disease and their levels 
increase with increasing disease severity. 
HYPOTHESIS 
1. Probable inflammation spreading over to CVS, CNS etc. 
2. A pro inflammatory phenotype is happening independent of lung 
component in systemic inflammation. 
TRIGGERS 
1. Smoking an important risk factor for the disease per se by way of 
endothelial function dearangement and oxidative stress to the tissues. 
2. Hypoxia of severe disease enhances HIF – 1 expression, upregulates 
genes invlolved in new vessel formation, inflammation, vascular 
remodelling. TNF  alpha levels have been shown to be in correlation 
with hypoxemia severity and that the enhanced survival of patients on 
LTOT might be due to fact that oxygen decreases inflammation. 
3. Increased leptin levels and its receptors 
  
4. Autoimmune process 
5. Oxidative stress of the disease shorten the telomere and causing 
ageing of lungs and other systems. 
CONSEQUENCES 
The consequence of the systemic inflammatory process are non 
pulmonary morbidities and mortalities shown to have immediate cause 
effect relationship across studies consistently and also have been 
identified that their association is not just by chance. 
CARDIOVASCULAR SYSTEM 
1. CORONARY ARTERY DISEASE 
These patients have three fold increased risk of developing CAD and 
the mortality rates in these patients due to CAD are correlate to those 
due to worsening of disease per se. cardiac injury biomarkers are 
increased in studies during acute exacerbations when the level of 
systemic inflammation is high. 
2. ARRHYTHMIAS 
The common rhythm disturbance include  
a. multifocal atrial tachycardia 
b. ventricular tachycardia 
c. atrial fibrillation 
  
3. CARDIAC FAILURE 
Cardiac failure is precipitated by end diastolic pressure changes 
induced by pressure variation caused by hyperinflation which 
interferes with ventricular remodelling.  
     SKELETAL MUSCLE WASTING 
1. More common in patients with severe COPD 
2. Proposed mechanisms include reduced IGF-1, decreased IL-6, decreased 
testosterone, decreased intake, hypoxemia. 
3. Fat mass will be relatively preserved when compared to skeletal muscle 
mass. 
4. It will have ill impact on exercise capacity and respiratory function. 
It is one of the negative predictor for outcome in COPD patients. 
OSTEOPOROSIS 
1. Seen in COPD patients who have never been on steroids 
2. It is related to tumour necrosis factor alpha and IL-1. 
3. It helps the macrophages to convert to osteoclasts. 
4. Other factors that may worsen the problem are increasing age, 
smoking, malnutrition, poor physical activity. 
METABOLIC SYNDROME AND DIABETES MELLITUS 
  
Undoubtedly, increased prevalence of diabetes in COPD patients are 
seen due to systemic inflammation which is strengthened by finding of 
elevated levels of inflammatory markers such as TNF alpha, IL-6 and 
CRP which further compounds the risk for developing CVD. 
DEPRESSION 
Increased prevalence due to  
1. systemic inflammation  
2. dependence due to increased disability  
3. impaired quality of life. 
PULMONARY HYPERTENSION IN COPD 
Mild PHT to some extent occur in most of the patients with advanced 
disease and rarely severe pulmonary hypertension in few. 
CAUSES 
1. Pulmonary vasoconstriction due to alveolar hypoxia acidosis, 
hypercapnia. 
2.  There is decrease in small vessels in areas of destroyed lung tissue 
due to terminal air space destruction seen in patients with 
emphysema. 
3. Increased lung volume leading to compression of pulmonary 
vessels. 
  
4. For every acute exacerbation there is approximately 20 mm of hg 
rise in pulmonary arterial pressure. This ultimately end up in 
pulmonary hypertension in repeated exacerbation. 
MECHANISM OF PULMONARY HYPERTENSION BY 
HYPOXIA 
1. Vascular intimal thickening 
2. Distal vessels vascularisation 
3. Hypertrophy of the vascular media of the proximal vessels. 
TREATMENT 
Pulmonary vasodilators result in worsening of V/Q mismatch because 
it is not the level of pulmonary hypertension but the degree of hypoxia 
which produce the clinical symptoms and that these drugs further 
worsen the situation. 
The only proven treatment is oxygen therapy which decreases both 
morbidity and mortality. 
To keep the haemoglobin  in upper limit of normal because low 
haemoglobin  is not tolerated in these patients due to hypoxemia. 
Nocturnal or ambulatory SaO2 can assist in optimal O2 concentration. 
COR PULMONALE  
  
it can happen either acutely during exacerbations or chronically due to 
disease progression and worsening gas exchange and produces 
irreversible vascular remodelling. 
DIAGNOSIS 
1. Echocardiogram 
To identify the presence of right ventricular enlargement but the 
study is difficult due to hyperinflated lungs and rotation of the 
heart. It can be supplemented by ABG-showing PaO2 < 50 mm Hg 
and Pco2 >50 mm hg. 
2. Electrocardiogram 
3. Cardiac catheterization – the gold standard investigation. 
MANAGEMENT  
1. Acute cor pulmonale 
a. Treatment of the precipitating cause 
b. Supplemental o2 to maintain adequate oxygenation. 
2. Chronic cor pulmonale 
Should be very careful while using diuretics and digoxin in 
patients with cor pulmonale because it sensitizes the heart to 
digoxin and precipitates life threatening rhythm disturbances in 
the presence of hypoxia and acidosis. 
3. Oxygen 
  
SPIROMETRY IN COPD 
The test to confirm or refute a diagnosis of the disease is 
spirometric evaluation as suggested by GOLD. As of them a post 
bronchodilator Forced expiratory volume 1/ Forced vital capacity < 
70% is used for diagnosis and the previous concept of absence of 
post bronchodilator reversibility has been abandoned. Spirometry 
has its own limitations and therefore a combination of clinical 
symptomatology and spirometry improves the diagnostic accuracy. 
ELECTOCARDIOGRAM IN COPD 
Chronic obstructive airways disease influence the electrical events of the 
heart in the following basic respects: 
1. the voluminous lungs have an insulating effect and thereby diminish the 
transmission of electrical potential to the registering electrodes 
2. the heart descends to a lower position within the thorax due to a 
lowering of the diaphragm. This will alter the position of the heart 
relative to conventional precordial electrode postions. 
3. the right ventricle and right atrium become compromised due to a 
reduction of the pulmonary vascular bed. This will result in right 
ventricular hypertrophy as well as right atrial enlargement.this right atrial 
enlargement lead to change in P wave vertical axis. 
Decreased magnitude of the electrocardiographic deflexions 
  
The voluminous lungs impair electrical transmission. The QRS and T 
deflexions are therefore markedly diminished in magnitude. 
Lead I sign 
In patients with COPD the frontal plane P, QRS and T wave axes are not 
infrequently all directed at around + 90 degree which are either precisely or 
almost perpendicular to the standard lead I axis. As a result of this Lead I 
reflects absent or very low amplitude P, QRS and T wave complexes giving the 
appearance of minimally disturbed base line. This ECG phenomenon is known 
as the Lead I sign. 
Right atrial enlargement 
          Depolarization of atrium represented by the P wave. Normal frontal plane 
P wave axis is directed to the right of +60 degree. In lead I and lead II and left 
precordial leads, the P wave is upright. Lead III biphasic P wave may be seen 
.Initial positive portion of the P wave indicate, activity of right atrium. Terminal 
negative portion indicate, activity of left atrium. 
       The cause for P-axis verticalisation in lung hyperinflation is that the right 
atrium is sturdy attached to the diaphragm by means of  dense pericardial 
ligament around the inferior vena cava. Due to progressive flattening of the 
diaphragm, the right atrium is distorted/displaced inferiorly causing a significant 
rightward deviation (verticalisation) of the P-wave axis. 
In contrast, in pure restrictive (fibrotic) lung disease, correlating with the degree 
of diaphragmatic elevation, the P-wave axis tends to be horizontal or leftward. 
  
The vertical P wave axis degree inversely correlating with FEV1, directly 
proportional to disease severity  
     
P pulmonale 
It is reflected by P waves which are tall and peaked in standard leads II, 
III, aVF, and is the expression of right atrial enlargement. 
The combination of right axis deviation and tall peaked P waves is 
Called P pulmonale. A comparison of interstitial pulmonary fibrosis and COPD 
showed that a deviation of the frontal plane P wave axis to the right of +70 
degree only occurs with COPD. 
Abnormalities of the QRS complex 
Right QRS axis deviation 
The frontal plane QRS axis is deviated to the right and commonly 
directed to +90 degree. When it is deviated further, the frontal plane leads will 
usually reflect an S1Q3R3 pattern. In very severe cases it may be directed to 
the “northwest” region. 
 
 
Left QRS axis deviation 
This occurs in about 10% of cases. The mechanism is still speculative. 
S1, SII, SIII syndrome 
Prominent terminal S waves may appear in standard leads I and II or in 
  
I, II and III giving rise to the SI, S II, S III syndrome. This indirectly reflects 
posterior displacement of the apex. 
Posterior displacement of the mean QRS axis 
The mean QRS axis may also be displaced somewhat posteriorly so that 
it tends to be more obliquely oriented to the horizontal plane. 
13 
Abnormalities of the precordial QRS form 
There is diminution of QRS magnitude in all the leads. It is not 
uncommon for all the precordial leads to reflect rS complexes. In very severe 
cases the R : S ratio is usually less than 1 in leads V4 to V6, and R wave 
amplitude in lead V6 may be less than 5 mm. The transition zone is frequently 
displaced to V6 or even further to the left. 
Right bundle branch block 
There may occasionally be transient complete or incomplete RBBB with 
an exacerbation of the emphysema and increase in oxygen desaturation. 
Right ventricle hypertrophy is mainly reflected by: 
a. right axis deviation 
b. prominent terminal S waves in the left precordial leads 
The single most characteristic ECG feature of diagnosis in COPD is said 
to be P wave axis of +70 to +90 degrees. 
Abnormalities of T waves 
Frontal T wave axis 
  
It is usually similar in direction to that of QRS axis. The T wave is 
diminished in amplitude in all leads. The T wave may be inverted in the right 
precordial leads especially when pulmonary hypertension is marked. 
Exacerbation of the disease with an increase in oxygen desaturation may 
be associated with elevation of ST segment in leads II, III and AVF. This 
manifestation is reversible. 
              
 
 
 
          USES 
1. Diagnosis 
2. Grading of severity In COPD patients the rate of decrease in 
forced expiratory volume 1 per year is about 75-100 ml in sharp 
contrast to normal persons’ 30 ml/ year. 
3. Lung “age” assessment 
By correlating patient’s FEV1 to the predicted FEV1 of his age 
matched control. It may be used to encourage smokers to quit 
smoking. 
4. Detection of upper airway obstruction 
  
5. Pre-operative evaluation 
These patients have a higher chance of developing post-
operative pulmonary complications. 
1. Thoracic surgery 
Predicted post operative FEV1 is calculated by applying 
“rule of 5” in that 1/5th function is contributed by each lobe 
and the predictive post operative value is calculated by lobe 
to be removed. A PPO FEV1 < 40% predicted is a contra 
indication to surgery. 
2. Non thoracic surgery 
Factors predicting post-operative complications are 
a. FEV1/FVC < 50% 
b. Maximum voluntary ventilation< 50% 
c. FEV1 or diffusing capacity <20% predicted 
d. High partial pressure of Co2 
e. Short distance of surgical site from the chest 
SMOKING CESSATION 
Smoking cessation is most important intervention in stopping the disease 
process. 
APPROACH 
  
A. Counselling 
B. Pharmacological assistance. 
COUNSELLING 
Counselling either by the clinician or non clinician increases cessation rate 
many times than self initiated attempts. 
5A intervention approach 
1. ASK – information about tobacco use at every visit. 
2. ADVICE – should be strong and individualized depending on patient’s 
health status and other considerations. 
3. ASSESS – patient’s willingness. If patient is not willing he should be 
insisted to quit. 
4. ASSIST – by speaking with the patient a give up plan; setting a date to 
stop smoking in the next 2 weeks, to reduce alcohol use, educate 
households and providing psycho social support. 
5. ARRANGE – follow-up. 
PHARMACOTHERAPY 
First line agents 
Nicotine replacement therapy 
Formulations available 
  
Gum 
Dose : 2 mg – 1-24 cigarettes/d; 4mg ->25 cigarettes/d 
Duration : 12 weeks 
Adverse effects : dyspepsia 
Lozenge 
Dose : 2mg – first smoke > 30 min after waking up from bed; 4mg – first 
smoke < 30 min after waking up from bed. 
Maximum of 20 mg/d 
Duration : 12 weeks 
Side effects : nausea, insomnia. 
Inhaler 
Dose : 6-16 cartridges of 4 mg each/d 
Duration : 6 months with dose reduction in last 3 months 
Side effects : rhinitis, local irritation 
Spray 
Dose : 0.5 mg in Each nostril 1-2 doses/he 
Maximum 5/he 
  
Duration : 3-6 months 
Side effects : local irritation 
Patch 
Dose: 16 or 24 hr patch for total duration of 8 weeks with dose reduction 
Side effects : local skin reaction, insomnia 
Advantage : good compliance, requires less skill. 
Contra indication to NRT : 
1. CAD – MI or unstable angina 
2. CVA 
3. Untreated acid peptic disease 
Bupropion sustained release 
Mechanism of action 
nor-epinephrine and dopamine reuptake inhibitor  
dose : 150 mg once daily x 3 days; 150 mg bd x 7-12 weeks 
duration: 6 to 12 months 
side effects : insomnia, dry mouth 
contra indications : epilepsy, MAOI use in past 2 weeks 
  
particularly preferred in patients with concomitant depression 
varnecline 
mechanism of action 
 partial agonist of nicotinic ach receptor 
dose : 0.5 mg od x 1- 3 days; 0.5 mg bd x 4-7 days; 1mg bd from then up to 
8 weeks. 
Side effects : CNS – suicidal intention which has resulted in FDA  warning. 
Second line agents 
1. Clonidine : 
Mechanism of action : post synaptic alpha2 agonist 
Dose : 0.1 – 0.4 mg/d x 2-6 weeks 
2. Anxiolytics 
Diazepam, buspirone, beta blockers 
3. Sensory replacement 
Citric acid inhaler, denicotinised tobacco, black pepper extract. 
4. Acupuncture : by releasing endorphins 
ANTAGONISTS 
   Mecamylamine 
Non competitive CNS and PNS nicotine receptor antagonist 
  
1. Naltrexone 
Aversion causing drugs 
Silver acetate – poor compliance 
SMOKING PREVENTION 
Smoking behaviour in around 90% smokers were initiated during 
adolescence. So prevention is more important and effective than 
cessation after the behaviour has begun. 
Measures : 
1. Health education – target population : adolescents, young adults 
2. Public health programs 
3. Smoke free public places. 
EMERGING THERAPIES 
The imbalance between pulmonary oxidant load and anti-oxidants 
leads to oxidative stress and causes inflammation and airway 
modelling. This functions as an important pathogenetic mechanism 
and probably the reason for steroid resistance and so has been 
targeted for newer therapies. 
So newer drugs are developed with the aim to inhibit this one of 
the several steps involved in the inflammatory pathogenesis of 
COPD with the concern of developing effective but also safe drugs. 
SMOKING CESSATION 
  
Smoking cessation is considered to be an important and effective 
intervention to halt the decline of lung function beyond any doubts. 
And now recent research has developed anti-free nicotine 
antibodies. 
These anti free nicotine antibodies bind with free nicotine denying 
their access across the blood brain barrier. And hence nicotine from 
cigarettes cannot stimulate nicotine receptors causing smoking an 
unpleasant experience 
NEWER BRONCHODILATORS 
Bronchodilators provide immediate symptom relief even though 
they do not arrest the disease process and thereby improve 
wellbeing of the patient. Hence this serves as an important 
component of the treatment plan. 
So for this purpose, newer long and ultra long acting 
bronchodialtors have been developed with the aim of meeting the 
short comings of short acting ones which is poor compliance due to 
multiple dosing. These ultra long acting bronchodilators are ultra 
long acting muscarinic antagonists and ultra long acting beta2 
agonists. 
ULTRA LONG ACTING MUSCARINIC ANTAGONISTS 
These agents have been shown to decrease the number of 
exacerbations besides providing long acting bronchodilatation and 
  
so they have the ability to attenuate the disease process partially 
and hence provide mortality benefit. 
DRUGS UNDER RESEARCH : 
1. Dexpironium 
2. Daratropium bromide 
3. Aclidinium 
4. TD-4208 
5. GSK-573719 
6. Glycopyronium bromide 
ULTRA-LONG ACTING BETA2 AGONISTS 
This includes 
1. Vilanterol – safe and efficacious 
2. Indacaterol – approved in Europe and USA 
3. Carmoterol – using modulate technology, the amount of inhaled 
drug reaching the target has been increased. 
4. GSK-642444 
5. MILVETEROL – PROVED EFFICACIOUS IN ASTHMA, 
NOT YET RESEARCHED ON copd 
6. BI-1744-CL 
7. UK-503590 
8. Compound X 
  
NOVEL COMBINATIONS 
Rationale of combining long acting drugs 
1. Synergism between two agents 
2. Patients are analysed whether beta or muscarinic receptor 
predominance in their airway respond to their respective drugs 
more than the other. So that their combination can overcome the 
problem of receptor variation. 
Though several combination of these agents along with steroids to 
decrease exacerbations are under development, there is a potential 
limitation of using these combination. The limitation is that 
delivery of these agents at different site which decrease their 
synergism. But still a solution which could overcome these 
limitation has been witnessed. It is by combining them into a dimer 
which serves to deliver the agents at the same site – dual acting 
muscarinic antagonist beta 2 agonist. 
Even other combinations under development are combining a 
LABA with an ICS or combining LABA with inhaled steroid and 
LAMA. 
ANTI INFLAMMATORY DRUG 
  
Over the decades there has been search for an effective and safe 
anti inflammatory drug with the potential of reducing lung 
inflammation. But still it has turned out to be in vain. 
But one of the recent break through finding is that oxidative stress 
causing decrease in HDAC in these patients has been the reason for 
corticosteroid unresponsiveness in them. And that theophylline 
increases this enzyme at cellular levels. Hence theophylline has 
made a comeback in the management of the disease with the aim of 
additive anti inflammatory effect when given with steroids and 
studies are underway. 
PDE-4 INHIBITORS 
Phosphodiesterase-4 is an enzyme found specifically in most 
inflammatory cells. This has been targeted to reduce the 
inflammatory process of the disease. So a selective PDE-4 inhibitor 
has been approved for use. This has shown to increase FEV1 
comparatively much better than tiotropium. And hence these drugs 
could be the best adjuvant therapy with bronchodilators. It is under 
study to introduce an inhalational form of this class. The key 
problem is that the side effects of this drug – gastro intestinal and 
upper respiratory tract effects. And this has led to search for 
development for specific inhibitors. 
  
ANTIPROTEASES 
As discussed earlier. An important pathogenetic mechanism of 
emphysema is an imbalance between proteases and anti proteases. 
Anti proteases such as MMP inhibitors have shown promising 
results in preventing emphysema. But few drugs of this class are 
under phase II and phase III trials. 
1. AZ11557272 – dual MMP-9/MMP-12 inhibitor 
2. Marimastat – non selective MMP inhibitor 
CYTOKINE INHIBITORS 
Obviously TNF alpha and other interleukins – notably IL-6, IL-7, 
IL-1beta are important cytokines responsible for the systemic 
inflammatory process in the disease. But still drugs targeting these 
cytokines are only in the budding stage. 
CHEMOKINE ANTAGONISTS 
CXCR1/2 receptor mediates the effects of chemokines on 
inflammatory cells. Oral AD28309, which is the antagonist to these 
receptor has shown to reduce inflammation in man. CXCR 3 and 5 
are other receptors targeted and drugs involved in these have 
finished phase I trials. 
TGF BETA INHIBITORS 
  
TGF beta causes small airway fibrosis and hence results in 
decrease in FEV1  and reduced exercise capacity. SD-280 is a 
class which inhibits this fibrogenic cytokine has been developed 
for this purpose but the long term consequences of this class are yet 
unknown. 
NFKB INHIBITORS 
NFKB is a transcription factor involved in upregulating the 
production of various chemokines, TNF ALPHA and MMP-9. And 
hence inhibition of this transcription factor seems to be a potential 
option. But such inhibitors are presently under research. 
P38MAPKinase INHIBITORS: 
P38MAPKinase is an enzyme which upregulates the production of interleukin 
8, TNF ALPHA and few other mediators causing inflammation. Inhaled 
formulation of inhibitors of this enzyme are now in development period. 
PHOSPHOINOSITOL-3-KINASE INHIBITORS under research. 
PPAR AGONISTS 
The drugs currents being studied for immunomodulatory effects of PPAR alpha 
and gamma are rosiglitazone and SB-219994. 
 
  
ANTIOXIDANTS 
Anti oxidant drugs being used are 
1. NAC and its derivatives 
a. N-Acetyl Cysteine 
i. Decreases systemic and pulmonary oxidative stress 
ii. Mild bronchodilation 
iii. Reduces exacerbation 
iv. Halts decrease in FEV1 
b. N-acestelyn – well tolerated 
c. Erdosteine – added advantage of reducing bacterial adhesion thereby reducing 
exacerbations. 
d. Procysteine – toxic 
e. Carbocysteine 
f. N – isobutyryl cysteine – less effective 
2. NRF-2 activators 
STATINS 
There are plenty of pleomorphic action of statins apart from lipid lowering 
action such as  
1. Anti oxidant 
2. Endothelial protection and 
  
3. Anti inflammatory properties 
4. Reduce exacerbations 
5. Decrease need for assisted ventilation  
6. Improving functional capacity 
7. Reduce FEV1 decline 
But randomised controlled trials are required to confirm their effectiveness to be 
included in the management plan of COPD. 
 
 
REGENERATIVE THERAPIES 
There are plenty of modalities to decrease or bring the destroyed lung back and 
hence restoring the normal anatomy. But currently only research is focusing on 
these modalities which in future if discovered might revolutionize the COPD 
management. 
STEM CELLS 
Restoration of alveolar tissue can be achieved by allogeneic mesenchyme stem 
cells but this modality has a main disadvantage. i.e. it may lead to an 
undesirable outcome of clogging of pulmonary vasculature with these cells. But 
still trials are currently under research to overcome this undesirable side effect. 
RETINOIC ACID 
Regeneration of distal respiratory unit can be achieved by ATRA and it also 
reverses emphysema but these benefits had not been shown in clinical trials. 
  
ANTI-AGEING THERAPY 
Accelerated ageing is found to be caused by oxidative stress which increases 
DNA damage mediated by inactivation by SIRT1 or SIR2 protein1. And this is 
being focused as a target for arresting the disease process. 
These discoveries are going in progress on one side. On the other side research 
are also on to find a better way of enhancing the amount of drugs delivered to 
the desired segment of lung by using either new carrier formulation, liposomal 
formulations, nanotechnology or agents to enhance absorption such as 
surfactant, taurocholate, hyaluronic acid etc. 
The best and most effective intervention is cessation of smoking though several 
hundreds or thousands of newer treatment modalities/drugs may emerge. 
 
 
  
MATERIALS AND METHODS : 
STUDY POPULATION: 
The study is to be conducted on 100 patients of Government Rajaji 
Hospital, who are all attending internal medicine and thoracic medicine op with 
clinical features and ECG changes of COPD    
INCLUSION CRITERIA: 
1. Age >45 year  
2. Normal sinus rhythm with ECG change  
3. past medical history of COPD 
4. Imaging studies with COPD changes 
5. Pulmonary function tests with COPD changes 
EXCLUSION CRITERIA 
1. Congenital heart disease  
2. valvular heart disease 
3. Cardiomyopathy.  
Most of the patients were diagnosed clinically and after radiological 
investigation.  
 
 
  
ANTICIPATED OUTCOME: 
 Vertical axis of P wave inversely correlating with pulmonary function 
test in COPD          
  
DATA COLLECTION:  
         All the patients selected for study are confirmed cases of COPD. 
 
LABORATORY INVESTIGATIONS: 
1) X ray chest 
 2)  ECG 
 3)  Pulmonary function test 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
STUDY PROTOCOL 
DESIGN OF STUDY: 
 Observational study  
 
PERIOD OF STUDY: 
  July 2014 to October 2014 
 
ANALYSIS: 
  Statistical analysis 
 
PARTICIPANTS: 
Patients attending in medicine and thoracic medicine op with 
clinical features and ECG changes of COPD 
CONFLICT OF INTEREST:  
NIL 
FINANCIAL SUPPORT:   
NIL 
 
 
  
  
 
 
  
  
OBSERVTION AND RESULTS 
                A total of 100 cases were studied. Data collected from patients were 
entered in Microsoft excel 2010 spread sheet and analysed with simple 
statistical  analysis 
                          
 
 
 
 
 
    Table 1 Distribution of patients in each stage 
 S.No Stage  No. of patients  percentage 
1.   I           20       20 % 
2.   II           15       15 % 
3.   III           31       31 % 
4.   IV           34       34 % 
Total           100     100 % 
 
of the 100 patients ,20 patients (20%) were in stage I, 15 patients (15%) were in 
stage II, 31 patients (31%) were in stage III, 34 patients (34%) were in stage IV. 
 
 
 
 
 
 
 
  
 
 
Chart 1 Distribution of patients in each stage 
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Table 2   Age distribution of  patients in each stage 
Age distribution Stage I Stage II Stage III Stage IV  Total 
 40 – 50     6      4      10      0     20 
 51 – 60     7      6        8    12     33 
 61 – 70     7      5        6      7     25 
 71 – 80     0      0        7    15     22 
  Total    20     15      31     34   100 
 
 
 the maximum number of patients belonged to the 51-60 age group and 40 -50 
age group constitute the minimum  
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  Table 3 Mean age distribution in each stage 
 S.no  stage  Mean age ± SD 
1.   I 57.95 ± 7.39 
2.   II 56.73 ± 8.08 
3.   III 60.09 ± 10.74 
4.   IV 66.52 ± 8.54 
            p <0.001 significant 
 
                 AGE WITH FEV1 % OF PREDICTED VALUE 
FEV1 PV P VALUE 
AGE 0.004 
 
      The increasing in age with the increasing stage of the disease was found 
statistically significant with p <0.001 and the correlation of age with FEV1 % of 
predicted value was found to be statistically significant 
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Table 4  No of patients according to smoking habits 
Smoking  Habits  No of patients % of  patients 
Smokers       67           67 % 
Non smokers        33            33 % 
 
Of the 100 patients 67 patients belongs to smoker and 33 patients are non-
smokers  
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Table 5  Sex distribution according to stage 
 
Stage 
      Male       Female  
No. of patients       % No. of patients       % 
  I 
       16   21.9          4     14.8 
  II 
        9   12.3          6     22.3 
  III 
       24    32.9          7     25.9 
  IV 
       24    32.9         10     37 
Total          73    100         27    100 
 
                  of the total 100 patients 73 patients were male and 27 patients were 
females . 
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TABLE 6 OCCUPATIONS 
S.NO        OCCUPATION 
 
  No of patients  Percentage (%) 
1 Manual labourers 60 60  
2 Dye industry 9   9 
3 Professional 10 10 
4 Flour mill 10 10 
5 Business 4   4 
6 Cotton industry 7   7 
Total  100 100 
 
 
 
Of the total of 100, Manual labourers were 60, Dye industry workers were 9, 
Professional were 10, Flour mill workers were 10, Business were 4, Cotton 
industry workers were 7. 
 
 
  
 
 
 
 
 
Table 7   symptoms  
S.NO   Symptoms    No. of patients  
1  Chronic cough   100 
2 Sputum production    70 
3 Breathing difficulty    90 
4 Wheeze     80 
 
All the patients had chronic cough, 70 patients with sputum production,  
90 patients with Breathing difficulty, 80 patients with Wheeze. 
 
 
 
 
  
  
 
 
 
 
 
 
Table 8 SIGNS  
S.NO     signs  No. of patients  
1 Elevated JVP         35 
2 Pedal edema         27 
3 Diminished air entry         75 
4 Rhonchi          90 
5 Crackles         52 
6 Downward displacement of liver         42 
 
 
Of the 100 patients, 35 had Elevated JVP,27 patients had Pedal edema , 
75 patients had Diminished air entry, 90 patients had Rhonchi, 52 patients  
had Crackle and 42patents had downward displacement of liver 
  
  
 
 
 
 
 
 
Table 9    Chest X ray PA view 
Stage No. of 
patients 
Normal  Chronic 
bronchitis 
Emphysema Chronic 
bronchitis + 
Emphysema 
  I 20 20 0 0 0 
  II 15 6 5 4 0 
  III 31 0 10 17 4 
  IV 34 0 5 24 5 
Total  100 26 20 45 9 
 
 
 
Of the 100 patients, 26 patients had normal X ray,20 patients had chronic 
bronchitis picture,45 patients had emphysema picture,9 patients had both 
chronic bronchitis and emphysema picture 
  
  
 
 
 
 
 
 
Table 10   ECG Changes 
ECG I II III IV 
RAE 0 7 15 20 
RVH 0 0 12 18 
RAD 3 0 12 18 
RBBB 0 3 13 10 
Lead 1 sign 0 10 27 30 
P wave changes 20 17 31 34 
.  
Among the total of 100 patients ,42 patients had feature of RAE,30 patients had 
feature of RVH,33 patients had feature of RAD,26 patients had feature of 
RBBB,67 patients had feature of Lead 1 sign,100 patients had feature of P wave 
changes. 
  
  
 
 
 
Chart 10  ECG Changes 
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Table 11   Echocardiography Changes 
Stage No. of 
patients 
Mild PHT Moderate 
PHT 
Severe 
PHT 
RV 
Dilatation 
  I 20 0 0 0 0 
  II 15 7 3 0 0 
  III 31 0 12 7 5 
  IV 34 0 15 9 10 
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Table 12 P wave vertical axis according to stage 
Stage      P wave vertical axis in degree NO.PATIENTS 
65-70 71-75 76-80 >80 
  I 13 7 0 0 20 
  II 4 11 0 0 15 
  III 0 1 10 20 31 
  IV 0 0 10 24 34 
Total  17 19 20 44 100 
 
Among 100 patients, 17 patients had P wave vertical axis of 65-75 degree,19 
patients had p wave vertical axis of 71-75 degree,20 patients had P wave 
vertical axis 76-80 degree,44 had P wave vertical axis of >80 degree.     
P wave vertical axis>80 degree  is superior to P wave vertical axis 75 -80 
degree is correlating with COPD severity and statically significant  as P value is 
< 0.005.   
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DISCUSSION  
               
                     In India, COPD is the second most common lung disorder after 
pulmonary tuberculosis. The disease is frequently encountered in middle aged 
patients and COPD has increasing public importance around the world. 
Estimates suggest that COPD will rise from the 6th to the 3rd most common 
cause of death worldwide by 2020. In our study total of 100 patients were 
studied after applying the inclusion criteria and exclusion criteria: their P wave 
vertical axis and severity of COPD assed by pulmonary function test. 
AGE  
In our study, the increasing age of the patients shows increasing stage of the 
diseases was found to be statistically significant with P <0.001 and the 
correlation of age with the FEV1 of predicted value was found to statistically 
significant. The risk of developing the diseases has been shown to increase with 
age. This may be due to age related detoriation of lung function or increasing  
duration of smoking or sustained exposure to environmental exposure risk 
factor or a combination of any these, one confounding the effect of the others . 
  
SEX  
Of the 100 total 100 patients, 73 were males and 23 were females. This is 
because smoking, the important risk factor is common in male. 
SMOKING  
The study showed that there is an increasing severity of the disease as depicted 
by GOLD stage with the increasing in the number of pack years of smoking and 
it was statistically significant .also the decline in FEV1 % of predicted value 
also showed a negative correlation with the number of pack years of smoking 
which is consistent with other studies. Smoking in any form found has been 
regarded as the most important risk factor in almost every study for developing 
the disease and has been proven to have a dose – response relationship. On 
reviewing several studies on Indian males patients ,83.2 % were associated with 
smoking. 
OCCUPATION  
Of the total of 100, Manual labourers were 60, Dye industry workers were 9, 
Professional were 10, Flour mill workers were 10, Business were 4, Cotton 
industry workers were 7.several occupation which are associated with chemicals 
,noxious gases ,minerals , dust, cotton industry have been identified as risk 
factors and the risk is further compounded if smoking is also present. 
 
  
 
SYMPTOMS  
In our study , all the patients had chronic cough with sputum production and a 
majority had shortness of breath and wheeze – the cardinal symptoms of the 
disease. 
SIGNS 
Of the 100 patients, 35 had Elevated JVP,27 patients had Pedal oedema , 
75 patient had Diminished air entry, 90 patients had Rhonchi,52 patients had  
Crackle downward displacement of liver. 
X RAY CHEST PA VIEW 
Of the 100 patients, 26 patients had normal x ray,20 patients had chronic 
bronchitis picture,45 patients had emphysema picture,9 patients had both 
chronic bronchitis and emphysema picture.thses inference show that imaging 
could not be used to diagnose the diseases particularly in its early stages and 
also that two forms of the disease is not mutually exclusive as patients over time 
may develop features of the two. 
ELECTROCARDIOGRAM 
Among the total of 100 patients ,42 patients had feature of RAE,30 patients had 
feature of RVH,33 patients had feature of RAD,26 patients had feature of 
  
RBBB,67 patients had feature of Lead 1 sign,100 patients had feature of P wave 
changes. 
                                         Among 100 patients, 17 patients had P wave vertical 
axis of 65-75 degree,19 patients had p wave vertical axis of 71-75 degree,20 
patients had P wave vertical axis 76-80 degree,44 had P wave vertical axis of 
>80 degree.     
                                      P wave vertical axis>80 degree is superior to P wave 
vertical axis 75 -80 degree is correlating with COPD severity and statically 
significant as p value is < 0.005. 
                                      From this study increasing vertical axis of P wave in 
COPD directly correlate with diseases severity, and indirectly correlating with 
the FEV1 of predicted. 
 
  
  
             LIMITATIONS OF THE STUDY 
 
 
 
The study has its own limitations  
 the number of patients involved in the study “n” is small and hence 
generalization of the results of the study to be made with caution 
 The study population involved only the patients seeking medical 
care in our hospital which is a tertiary care hospital and hence they 
may not represent general population. 
 This study is a observational study. Longitudinal studies with serial 
assessment of the variables would be more informative. 
So, longitudinal studies with large study population and population 
based studies are needed to circumvent this limitation. 
 
  
 
 
  
CONCLUSIONS 
 
 
 
From our study we concluded that  
 increasing age is associated with severity of the disease  
 Males are more commonly affected then females because of 
smoking. 
 occupational exposure to risk factors compounds the risk of 
developing the disease when associated with smoking 
 incidence of pulmonary hypertension and right ventricular 
dilatation increase  with increase  in severity of the diseases 
 p wave vertical axis is directly proportional  to severity of 
COPD and inversely correlating with the FEV1 of predicted. 
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   PROFORMA 
Name :                Age/Sex/Occupation: 
Presenting complaints: 
H/o cough & expectoration,dyspnea,wheez. Etc. 
Past history: 
H/o COPD, diabeties,hypertention,tuberculosis,CVA,CAD,any chronic drug 
intake. 
Clinical examination: 
General examination: 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy,  
Vitals: PR, BP, RR, SpO2, Temperature,jvp 
Systemic examination:  
CVS: 
 RS:  
Abdomen : 
 CNS: 
  
LABORATORY INVESTIGATIONS  
1.ECG 
2.X RAY CHEST 
3.ECHO 
4.PULMONARY FUNCTION TEST 
  
  
ABBREVIATIONS 
COPD –chronic obstructive pulmonary diseases 
GOLD –global initiative for chronic obstructive lung disease 
ECG   -electrocardiogram 
FEV1 –forced expiratory volume in 1 second. 
FVC – forced vital capacity 
AT –anti – Trypsin 
RV – residual volume  
TLC –total lung capacity 
FRC – functional residual capacity 
ROS – reactive oxygen species 
MMP- matrixmetalloprotenase 
ABG – arterial blood gas 
PHT – pulmonary hypertension  
MAT – multifocal atrial tachycardia  
CAD –coronary artery disases 
NIV –non invasive ventilation  
  
TNF alpha-tumour necrosis factor alpha 
TGF BETA-transforming growth factor beta 
IL – interleukin 
NFKB – nuclear factor K B  
LTOT – long term oxygen therapy 
  
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
S.No       
            
        
 
Name 
 
AGE Sex FEV 1  p wave axis (Degree) 
 
  
 65 - 70 71- 75 76 - 80 >80 
1 MOHAN 51 M IV - - - + 
2 PANDIARAJAN 53 M IV - - - + 
3 IYYAMMAL 55 F IV - - - + 
4 AYYAVU 59 M IV - - - + 
5 LAKSHMANAN 46 M II + - - - 
6 
CHANDRAN 
56 M II - 
 
+ - - 
7 KANAGA VALLI 45 F I + - - - 
8 JAMUNA 49 F I + - - - 
9 SELVA RANI 46 F III - + - - 
10 SUMATHI 50 F III - - + - 
11 BAGHAYA LAKSHMI 60 F I - + - - 
12 MUTHU MANI 59 M IV - - + - 
13 JAYA LAKSHMI 65 F I - + - - 
14 SIVA SANKARI 46 F II + - - - 
15 BASHEER AHMEED 49 M II + - - - 
16 MANIKANDAN 47 M I + - - - 
17 IRULAYI 66 F II - + - - 
18 MARI MUTHU 77 M III - - - + 
19  
SONAI MUTHU 
46 M III - - - + 
20 ARJUNAN 55 M I + - - - 
21 ANGURAJ 71 M IV - - - + 
22 ESHWAR LAL 72 M III - - - + 
23 RAJAMMAL 66 F II - + - - 
24 PONAMBALAM 65 M IV - - - + 
25 RAGHAVAN 73 M III - - - + 
26 MALAIKANI 56 F II - + - - 
27 JAYAKUMAR 48 M III - - - + 
28 PREM 72 M IV - - - + 
29 RAJENDRAN 73 M III - - - + 
30 GURUVAMMAL 56 F II - + - - 
31 KUMAR 47 M III - - - + 
32 RAMESH 73 M IV - - - + 
33 PANJU 57 F II + - - - 
34 PALANIVEL 76 M IV - - - + 
  
35 MEENAKSHI 56 F III - - + - 
36 RANJITHAM 74 M IV - - - + 
37 ARUMUGAM 46 M II + - - - 
38 GANESAN 75 M III - - - + 
39 VIMALA 58 F III - - + - 
40 SUMATHI 65 F III - - - + 
41 KANNAN 75 M IV - - - + 
42 SANTHA RAM 47 M I + - - - 
43 VASANTHA 59 F III - - - + 
44 INDRA 55 F IV - - + - 
45 KASIRAJAN 49 M II - + - - 
46 THAVAMANI 65 F III - - + - 
47 MYTHILI 53 F IV - - + - 
48 VASUDEVAN 68 M I + - - - 
49 NARAYANAN 74 M III - - - + 
50 KALAISELVI 65 F III - - + - 
51 SUBRAMANI 56 M II - + - - 
52 SIVAGAMI 66 F IV - - - + 
53 SATHYA 73 F IV - - - + 
54 PRIYA 75 F IV - - - + 
55 SARAVANAN 48 M III - - + - 
56 SAHADEVAN 64 M IV - - - + 
57 PREM 59 M I - + - - 
58 KUMAR 66 M II - + - - 
59 SIVAKUMAR 55 M III - - - + 
60 JOTHI 66 F IV - - + - 
61 JEYABALAN 65 M I + - - - 
62 ATHI LAKSHMI 69 F IV - - - + 
63 RAVI MUTHU 60 M III - - - + 
64 RAMU 70 M I + - - - 
65 RAMESH KUMAR 67 M II - + - - 
66 RAJESH 65 M III - - - + 
67 RAJESHWRI 73 F IV - - + - 
68 PANNER SELVAM 78 M IV - - - + 
69 PACHAYAPPAN 59 M III - - - + 
70 PICHAI MANI 55 M I - + - - 
71 RAJU 63 M IV - - - + 
72 ULAKANATHAN 76 M III - - - + 
73 RAMU 59 M I - + - - 
74 KATHIR 69 M II - + - - 
75 VANKATESH 65 M I + - - - 
76 SRINIVASAN 47 M III - - + - 
77 SOMASUNTHARAM 54 M I - + - - 
78 NAATARAJAN 62 M IV - - - + 
79 MURALITHARAN 56 M III - - - + 
80 PRIYA 78 F IV - - + - 
81 SUNTHARI 73 F IV - - - + 
82 DHANALAKSHMI 75 F IV - - - + 
83 DENANATHAN 45 M III - - + - 
  
84 VINOTH KUMAR 77 M IV - - - + 
85 SENTHIL 55 M I + - - - 
86 AJITH 75 M III - - - + 
87 PRABU 59 M IV - - - + 
88 SELVARANI 54 F I - + - - 
89 KALAI SELVAN 79 M IV - - - + 
90 LARANCE 67 M III - - - + 
91 AJAI 70 M IV - - - + 
92 MOHAMAD JINNA 59 M I + - - - 
93 SANMUGAM 66 M III - - - + 
94 MURUGAN 58 M I + - - - 
95 MATHAN 57 M IV - - - + 
96 GOVINTHAN 49 M III - - + - 
97 SIVASITHAM BARAM  58 M IV - - - + 
98 HAHAMOD 70 M I + - - - 
99 ARUBI PRASATH 56 M IV - - - + 
100 ANADTH 46 M III - - + - 
 
  
  
  
  
 
 
  
  
 
